SPL7013 Gel (VivaGel®) Retains Potent HIV-1 and HSV-2 Inhibitory Activity following Vaginal Administration in Humans

SPL7013 Gel (VivaGel(®)) is a microbicide in development for prevention of HIV and HSV. This clinical study assessed retention and duration of antiviral activity following vaginal administration of 3% SPL7013 Gel in healthy women. Participants received 5 single doses of product with ≥5 days between...

Descripción completa

Detalles Bibliográficos
Autores principales: Price, Clare F., Tyssen, David, Sonza, Secondo, Davie, Ashley, Evans, Sonya, Lewis, Gareth R., Xia, Shirley, Spelman, Tim, Hodsman, Peter, Moench, Thomas R., Humberstone, Andrew, Paull, Jeremy R.A., Tachedjian, Gilda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3174146/
https://www.ncbi.nlm.nih.gov/pubmed/21935377
http://dx.doi.org/10.1371/journal.pone.0024095

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3174146/
https://www.ncbi.nlm.nih.gov/pubmed/21935377
http://dx.doi.org/10.1371/journal.pone.0024095

Ejemplares similares